Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects
Clinical Infectious Diseases2005Vol. 40(9), pp. 1358–1361
Citations Over TimeTop 10% of 2005 papers
Sonia Rodríguez‐Nóvoa, Pablo Barreiro, A. Rendon, I Jiménez‐Nácher, J. Gonzalez-Lahoz, Vincent Soriano
Abstract
We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus-positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.
Related Papers
- → Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy(2019)173 cited
- → Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry(2019)63 cited
- → CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans(2011)49 cited
- → Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients(2012)43 cited
- → Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers(2022)7 cited